Searchable abstracts of presentations at key conferences in endocrinology

ea0016p283 | Endocrine tumours | ECE2008

Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism in MEN-1 patients

Faggiano Antongiulio , Tavares Lidice , Milone Francesco , Mansueto Gelsomina , Ramundo Valeria , De Caro Maria Laura Del Basso , Lombardi Gaetano , De Rosa Gaetano , Colao Annamaria

Background: Expression of somatostatin receptor (SST) and therapy with somatostatin analogues have been scarcely investigated in parathyroid tumors.Objective: To evaluate the effects of depot long acting octreotide (OCT-LAR) on primary hyperparathyroidism in patients affected with multiple endocrine neoplasia type 1 (MEN-1).Subjects and methods: Eight patients with a genetically confirmed MEN-1 were enrolled. All patients presented...

ea0016p395 | Neuroendocrinology | ECE2008

Dopamine receptor expression and dopamine agonist effectiveness in corticotroph pituitary tumors: comparison with clinical, biochemical radiological and pathological features of patients with Cushing's disease

Pivonello Rosario , de Herder Wouter W , Ferone Diego , Kros Johan M , De Caro Maria Laura Del Basso , Lombardi Gaetano , Colao Annamaria , Hofland Leo J , Lamberts Steven WJ

Dopamine receptors (DR) are expressed in the majority of corticotroph pituitary tumors and the dopamine agonist cabergoline is effective in controlling cortisol hypersecretion in around 50% of patients with Cushing’s disease (CD). In order to characterize the tumors expressing D2 receptors and the profile of patients which might respond to the treatment with D2 agonists, the current study has the aim to correlate D2 receptor expression and...